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Abstract 
Histamine is a key mediator in allergic diseases, 
where it exerts most of its effects through the H1 
receptor and to a less extent the H2 receptor. H1- 
antihistamines provide rapid relief of many of the 
allergic symptoms and are considered the main 
stay of treatment of allergic rhinoconjunctivitis 
and urticaria. H1 antihistamines comprise first 
generation (old) and second generation (new) H 1 
antihistamines with different pharmacological 
aspects, efficacy and safety profile. Few studies 
dealt with H1 antihistamines in pediatric 
population. This review will highlight the 
characteristics of H1 antihistamines and their 
indications in pediatric allergic disorders. 
 
Allergic diseases constitute the most common 
causes of chronic illness in developed countries 
and the incidence rising in developing countries. 
It has been proposed that there is a worldwide 
epidemic of allergic diseases which is likely to be 
a consequence   of the changing environment and 
improved general health, superimposed on a range 
of genetic susceptibilities. Therefore, the 
treatment of allergy should have high priority in 
most countries.1 
Histamine (one of the key mediators released 
from mast cells and basophils), plays a major role 
in the pathophysiology of allergic diseases, 
including rhinitis, urticaria, asthma and 
anaphylaxis.2 The effects of histamine are exerted 
through three well defined classical G protein 
coupled histamine receptor (HR) subtypes termed 
H1R, H2R, and H3R3 and the more recently 
described H4R.4 There is also a fifth category 
including ill-defined histamine receptors such as 
an intracellular receptor labelled Hic. Its existence 
has so far only been inferred by the presence of 
small amounts of histamine in cells not 
traditionally thought to contain histamine5. All 
have constitutive activity, which is defined as the 
ability to trigger downstream events even in the 
absence of ligand binding.6 
Histamine signalling through H1R is 
responsible for the majority of the immediate 
manifestations of allergic disease namely pruritus, 
pain, vasodilatation, vascular permeability, 
hypotension, flushing, headache, tachycardia, 
bronchoconstriction, and stimulation of airway 
vagal afferent nerves and cough receptors as well 
as decreased atrioventricular-node conduction.  
However, certain effects such as hypotension, 
tachycardia, flushing, headache, itching and nasal 
congestion are mediated through both H1 and H2 
receptors.2,7 
Considering all the above roles of histamine 
on H1 receptors, it is clear that anti- 
H1antihistamines are the most common drugs 
used to treat allergic diseases.8 H1 antihistamines 
are not receptor antagonists as previously thought, 
but are inverse agonists.9 When neither histamine 
nor antihistamine is present, the active and 
inactive states of the H1 receptor are in 
equilibrium or a balanced state. Histamine 
combines preferentially with the active form of 
the receptor to stabilise it and shift the balance 
towards the activated state and stimulate the cell10.  
Antihistamines stabilise the inactive form and 
shift the equilibrium in the opposite direction. H1 
antihistamines reduce the expression of pro-
inflammatory cell adhesion molecules and the 
accumulation of inflammatory cells, such as 
eosinophils and neutrophils. Major clinical effects 
of H1 antihistamines are seen in suppression of 
the early response to allergen challenge in the 
conjunctiva, nose, lower airway and skin.2  
The anti-inflammatory effects of H1 
antihistamines are exerted through receptor- 
dependent and -independent mechanisms. 
Receptor-dependent mechanisms involve the 
stabilization of the histamine receptor in its 
inactive conformation.  A possible site where they 
could exert an anti-inflammatory activity is at the 
level of the transcription factors, NF-kB and 
GATA3. This would lead to inhibition of these 
factors dependent cytokines and adhesion 
molecules.8  
Receptor-independent effects consist of 
inhibition of inflammatory cell activation   
including the de novo generation of 
proinflammatory products such as superoxide 
radicals, and the arachidonic acid products LTB4 
and LTC4, and the release of granule associated 




eosinophil cationic protein. The suggested 
mechanisms include the inhibition of calcium 
mobilization and of the activity of membrane-
associated enzymes such as inhibition of protein 
kinase C and NADPH oxidase.  However, these 
actions require high drug concentrations, not 
corresponding to therapeutic dosages.8 
 
 
Figure 1. Simplified two-state compartment model of the histamine H1-receptor 
(Quoted from Leurs et al, 2002)10 
 
 
Classification of H1 antihistamines 
H1 antihistamines are classified into the older, 
or first generation antihistamines, and the 
newer or second generation antihistamines. 
The main differences between the two 
generations of drugs are their propensity to 
cause central nervous system side effects.2 
The first-generation H1 antihistamines 
such as diphenhydramine, chlorpheniramine, 
clemastine, triprolidine, cyproheptadine, 
brompheniramine and hydroxyzine are highly 
lipophilic and hence they penetrate well into 
the CNS where they induce sedation. 
Furthermore, first-generation antihistamines are 
very receptor non-selective, often exhibiting 
high affinity for dopaminergic, serotonergic, 
alpha-adrenergic, and cholinergic receptors in 
the brain.11,12 
The second-generation H1 antihistamines 
were first developed in the early 1980s to 
improve on the sedative and anticholinergic 
adverse effects.  However, two of these, 
astemizole and terfenadine, have serious 
cardiac side effects, resulting in prolonged Q-T 
intervals and arrhythmias and were withdrawn 
from the market. The currently available 
second-generation antihistamines include 
cetirizine, loratidine, desloratadine, 
fexofenadine, acrivastine, azelastine, and 
levocetirizine.11,13,14 The second generation 
antihistamines have improved H1 – receptor 
selectivity, absence or decreased sedation, 
faster onset and longer duration of action and 
fewer adverse effects.15 
 
Pharmacokinetics and dynamics of H1 
antihistamines 
The drug pharmacokinetic and 
pharmacodynamic characteristics can differ 
greatly depending on the age group considered. 
These characteristics determine efficacy and 
particularly safety, and make it possible to 
predict the behavior of a given drug in the 
body. In general, antihistamines are well 
absorbed following oral administration as both 
solid and liquid formulations, and reach 
maximum plasma concentrations between 1-4 
hours after dosing in both children and adults.16  
The bioavailability of fexofenadine may be 
altered by simultaneous consumption of 
grapefruit juice (reduced rate of absorption of 
the drug by almost 30%). However, grapefruit 
juice does not affect the absorption of other 
second-generation antihistamines.17 Although 
topical intranasal and ophthalmic H1 
antihistamines differ in their pharmacokinetics, 
most of the topical preparations need to be 
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administered twice daily because of the 
washout from the nasal mucosa or conjunctiva.2 
Most antihistamines are metabolized and 
detoxified within the liver by the group of 
enzymes belonging to the P450 cytochrome 
system. Only acrivastine, cetirizine, 
levocetirizine, desloratadine and fexofenadine 
avoid this metabolic passage through the liver 
to an important degree which makes them more 
predictable in terms of their desirable and 
undesirable effects. Cetirizine and 
levocetirizine are eliminated in urine, mainly in 
unaltered form, while fexofenadine is 
eliminated in stools following excretion by the 
biliary tract, without metabolic changes. The 
rest of antihistamines undergo liver 
transformation to metabolites that may or may 
not be active, and whose concentrations in 
plasma depend on the activity of the P450 
enzyme system.18,19 
The plasma half-life depends on the drug 
metabolization and clearance processes within 
the body, and although such processes are the 
same in both children and in adults, they are 
comparatively accelerated in children in the 
case of certain antihistamines. As a result, ideal 
dosing in such cases is once every 12 hours 
instead of once every 24 hours (e.g., in the case 
of levocetirizine in kindergarten children).20-22 
The activity of the liver enzyme complex can 
also be altered under special metabolic 
conditions such as infancy, advanced age, liver 
diseases or by direct drug action upon the 
enzyme complex.23-26 
Drug interactions resulting in a decrease in 
plasma concentration of the drug may lessen its 
clinical efficacy, as occurs when administering 
H1 antihistamines together with cytochrome 
P450 inducers such as the benzodiazepines.27 In 
other cases an increase in plasma concentration 
of the antihistamine can result, and its adverse 
effects may thus increase as well. This occurs 
when coadministering the drug with other P450 
cytochrome substrates that competitively 
inhibit its metabolism, such as the macrolides, 
antifungals or calcium antagonists.28 In these 
cases the safety margin of the antihistamine, 
i.e., the concentration range for which the 
incidence of adverse events is minimal, will be 
a very important consideration, since the 
plasma levels will be unpredictable. Thus, drug 
dose adjustment may prove necessary in all the 
above mentioned situations.18 
There are no studies of the effects of 
possible drug interactions in the pediatric age 
group between antihistamines and P450 
cytochrome inhibitors, or drugs which are 
metabolized via this pathway. The only 
exception is a study of children with 
chloroquine-resistant malaria, where the plasma 
concentrations of this drug were seen to be 
significantly greater, and were reached sooner, 
when administered in combination with 
chlorpheniramine.29  
The pharmacodynamic aspects, such as the 
onset of action and its duration, are studied 
both in children and in adults based on the 
histamine-induced skin wheal and erythema 
inhibition model. In the same way as in adults, 
no tachyphylaxis or tolerance of this effect on 
histamine-induced wheal and erythema 
production is observed.30 
 
Adverse effects of H1 antihistamines 
The different national and international drug 
agencies admit that there are currently many 
medicines authorized for use in children that 
have never been adequately investigated for 
application in such patients although in their 
day they received authorization out of a lack of 
regulation of the required specifications. In this 
sense, their use is still allowed because the 
pharmacovigilance systems have not detected 
any adverse effects requiring their withdrawal 
from the market.16 
First-generation antihistamines have the 
greatest serious adverse effects. There are no 
long-term safety studies on the first-generation 
antihistamines. These older antihistamines have 
potential for serious adverse effects such as 
CNS depression and cardiotoxicity, and have 
also been associated with fatalities in accidental 
and intentional paediatric overdose.31-33  
 
Central nervous system toxicity 
In a study of   24 children  diagnosed  with 
allergic rhinitis whose ages ranged between 7 
and 14 years  of age, both  chlorpheniramine 
and cetirizine induced significant cognitive 
alterations versus placebo, though such 
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alterations were not correlated to subjective 
appraisal of dysfunction as assessed by means 
of a visual analogue scale.34 
Multiple studies among adults have 
evaluated the effects that second-generation 
antihistamines have on the CNS. Loratadine 
and desloratadine were found to be comparable 
with placebo at therapeutic doses, but caused 
sedation when used off label at higher than 
recommended doses.  In contrast, fexofenadine 
has been found to be free of sedative effects 
even at higher than therapeutic doses.  
Memory, attention and tracking performance 
were unaffected after administration of 
levocetirizine compared with diphenhydramine 
and placebo.35-37 
An important point arising from 
antihistamine action upon the CNS is how such 
actions can affect school performance.  A 
clinical study comparing loratadine and 
diphenhydramine concluded that loratadine 
improved academic performance, in contrast to 
diphenhydramine, which worsened it. Another 
study evaluated the impact of long-term 
cetirizine treatment in children with atopic 
dermatitis-concluding that there were no 
adverse effects upon learning.38, 39 
There have been reports of many rare 
adverse effects in children administered first-
generation antihistamines, including spasms, 
seizures, aggression, respiratory distress, fixed 
skin rash, central anticholinergic syndrome, and 
toxic encephalopathy in patients with skin 
syndromes (atopic dermatitis, varicella) 
involving damage to the skin barrier, in which 




Cardiac toxic effects induced by H1-
antihistamines  occur rarely and independently 
of the H1- receptor and are not a class effect. 
First-generation H1-antihistamines have 
antimuscarinic and a-adrenergic blockade 
activity and may cause dose-related 
prolongation of the QT interval.31,35 
The absence of cardiotoxicity with 
antihistamines such as cetirizine, loratadine, 
fexofenadine and ebastine has been well 
established. Since they have been marketed 
only recently, both levocetirizine and 
desloratadine have been required to document 
the absence of such cardiotoxicity according to 
very strict criteria, based on the new demands 
of the international drug agencies, in order to 
be authorized for use in pediatric patients, 
though no published studies are available.48-50,16 
 
Clinical uses of H1-antihistamines in 
paediatric allergy 
H1 antihistamines currently constitute the 
largest class of medications used in the 
treatment of allergic disorder, the dosages and 
formulations of some of the second generation 
H1 antihistamines are displayed in table 1.2 
 
 Allergic rhinoconjunctivitis 
Allergic rhinitis (hay fever) is the most frequent 
chronic disorder in the pediatric population, 
and its prevalence is increasing. Although it is 
not life-threatening, it can have a significantly 
detrimental effect on a child’s quality of life, 
and it may exacerbate a number of common co-
morbidities, including asthma, sinusitis and 
seromucosal otitis.51-53 In Alergológica-2005 
Study, 44.7% of children, below the age of 14 
years, with atopy had allergic rhinitis and 61% 
of them had conjunctivitis but only 5% 
presented with conjunctivitis alone.54 
The use of H1-antihistamines is important 
for the treatment of allergic rhinitis in children, 
as many young children particularly prefer an 
oral medication to an intranasal medication.55 
In the same way as in adults, antihistamines are 
effective in alleviating most of the symptoms of 
pediatric allergic rhinitis: itching, rhinorrhea, 
and sneezing, though they appear to be less 
effective against nasal congestion. There are no 
randomized, controlled and masked clinical 
trials warranting the use of formulations that 
mix first generation antihistamines with nasal 
decongesting agents (systemic vaso-
constrictors), despite the fact that they are so 
often used in paediatric practice.16  
Regular daily administration is associated 
with a significant decrease in symptoms and 
nasal mucosal inflammation compared with 'as 
needed' or 'on demand' use.56 H1- 
antihistamines provide relief of allergic rhinitis 
comparable to that provided by intranasal 
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cromolyn sodium 4% and are generally found 
to be less potent than intranasal corticosteroids 
in the treatment of allergic rhinitis symptoms.  
Leukotriene receptor antagonists (LRAs) may 
also be effective in certain patients with allergic 
rhinitis if combined with an antihistamine.2 
While many second-generation H1-
antihistamines are effective and safe in the 
treatment of allergic rhinitis in children, only 
cetirizine, levocetirizine and loratadine have 
been studied for long-term efficacy and safety 
in children.57-59 The use of intranasal H1-
antihistamines like levocabastine and azelastine 
has the benefits of rapid onset of action and few 
adverse effects. These drugs are useful in 
children with symptoms limited to the nose or 
the eyes.60-62 
In allergic conjunctivitis, the ocular 
symptoms induced by allergen, such as itching, 
tearing and reddening are reduced by 
administration of H1 antihistamines either 
systemically or topically as eye drops such as 
azelastine, ketotifen, levocabastine and 
olopatadine. Topical application usually results 
in faster onset of action within 5 minutes than 
oral administration.63 Emedastine and 
levocabastine in ophthalmological solution 
have been shown to alleviate the symptoms of 
allergic conjunctivitis in children; symptoms 
reduction being significantly greater with 
emedastine than with levocabastine.64 
 
 Childhood asthma 
A recent epidemiological study conducted in 
Spain, Alergológica 2005,65 showed that in 
children less than 14 years of age with 
bronchial asthma, antihistamine treatment was 
indicated in up to 30% of cases. In many cases, 
asthmatic patients with rhinitis receive 
antihistamine treatment, and it has been seen 
that in such situations patient lung function 
improves significantly.66 Likewise; scientific 
evidence indicates that correct management of 
rhinitis is associated with a significant 
reduction in the risk of hospital admission 
and/or emergency care due to asthma attacks67. 
Antihistamines such as ketotifen, cetirizine 
and loratadine have shown a range of effects 
upon asthma: they reduce exercise-induced 
asthma attacks,68 improve cough in children 
with pollen allergy during the pollen season,69 
and improve asthma symptoms in children.70 
The improved specificity, tolerability, and 
safety profile of the second-generation H1-
antagonists associated with anti-inflammatory 
activities and bronchodilator activities, may 
contribute to relieve the symptoms of the upper 
and lower airways in patients with coexistent 
mild seasonal asthma and allergic rhinitis. 
Considering the global rise in the prevalence of 
allergy and asthma, the suggestion that H1-
antagonists may delay the onset of asthma in 
infants is of considerable interest and merits 
further assessment.71 
Antihistamines should never be used as 
monotherapy for asthma but there is evidence 
that these drugs give a measure of protection in 
histamine-induced bronchoconstriction. It is of 
interest to note that cetirizine provides a 
primary pharmacological intervention strategy 
to prevent the development of asthma in 
specifically-sensitized high risk groups of 
infants. Moreover, the documented anti-
inflammatory activities of antihistamines may 
provide a novel mechanism of action for the 
therapeutic control of virus-induced asthma 
exacerbations by inhibiting the expression of 
intercellular adhesion molecule-1 (ICAM-1) by 
airway epithelial cells.72 
 
 Atopic dermatitis 
In atopic dermatitis (AD), itching is one of the 
major symptoms and the resultant scratching 
usually causes worsening of the lesion. H1 
antihistamines may relieve itching and reduce 
scratching. Relief of itching by H1 
antihistamines is often incomplete in AD, 
because the itching produced by mediators 
other than histamine is not down-regulated.2  
H1 antihistamines appear to relieve itching 
mainly through their CNS effects and thus first-
generation H1 antihistamines (sedating) such as 
hydroxyzine and diphenhydramine are more 
effective for relief of itching in this disorder 
than are the second-generation H1 
antihistamines (non-sedating).73 The 
Alergológica 2005 epidemiological study 
showed that 73.6% of the children diagnosed 
with atopic dermatitis and included in the study 
were prescribed antihistamine therapy -a first-
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generation drug being involved in 20% of the 
cases.65 
However, studies have shown that second-
generation medications such as cetirizine and 
loratadine may also relieve itching in AD.74,75 
Cetrizine was found to reduce the duration and 
amount of topical corticoid treatment used in 
children with the worst atopic dermatitis.75 
 
 Acute and chronic urticaria 
H1 antihistamines are first-line medications in 
acute and chronic urticaria and very effective in 
providing symptomatic relief. The evidence 
base for the use of H1 antihistamines in acute 
urticaria remains small; however, recently, in a 
prospective, randomised, double blind, 
placebo-controlled, 24-month-long study, high 
risk children given cetirizine had significantly 
fewer episodes of acute urticaria than did those 
given placebo.2,76 
The second-generation H1 antihistamines   
(non-sedating) are the only drugs with class 1 
evidence and grade A recommendation.77,78  
They offer  good to moderate response in 44-
91% of all types of urticaria, and in 55% of 
patients with chronic urticaria. While the first-
generation H1 antihistamines (sedating) should 
be reserved for those patients not controlled 
with second-generation antihistamines, 
particularly when the symptoms interfere with 
sleep at night.79  
For the indication of chronic urticaria, only 
cetirizine, loratadine and desloratadine are 
approved for treatments in patients up to 2 
years of age, while ebastine and levocetirizine 
are only contemplated in the corresponding 
Summaries of Product Characteristics for 
urticaria in children over 6 years of age.80 
Night-time sedation with hydroxyzine, 
combined with the day-time use of a non-
sedating antihistamine such as cetirizine, 
fexofenadine, levocetirizine or desloratadine, is 




In anaphylaxis, H1-antihistamines relieve 
itching, flushing, urticaria, angioedema, and 
nasal and eye symptoms;81 however, they 
should not be substituted for epinephrine 
because they are not life-saving; that is, they do 
not prevent or relieve upper airway obstruction, 
hypotension, or shock.82-84  
Because first-generation H1 antihistamines 
such as chlorpheniramine, diphenhydramine, 
and hydroxyzine have high aqueous solubility 
and are available in parenteral formulations for 
injection, they continue to be widely used in the 
treatment of anaphylaxis. Most of the second-
generation H1 antihistamines have low aqueous 
solubility and none is available in formulation 
for injection.2 
Antihistamines also have a potential role in 
prevention of anaphylaxis. In idiopathic 
urticaria, patients with frequent episodes, that 
is, more than 6 in 1 year or more than 2 in 2 
months, are reported to benefit from 
prophylactic treatment   with   an H1-
antihistamine.85 Second-generation H1 
antihistamines, administered orally, prevent 
allergic reactions in patients receiving 
immunotherapy.86 
 
Table 1. Formulations and dosages of second-





dose Tablet  Syrup 
Cetirizine 10 mg 5mg/5ml 
2.5 -5 mg od 
(6mo- 5 yr) 
5-10 mg od (6-
11 yr) 
Loratidine 10 mg 5mg/5ml 
5 mg od (2-9 
yr) or 
10 mg od (6-11 
yr) 
Desloratidine 5 mg NA 







60 mg bd or 
120-180 mg od 
(≥ 12 yr) 
Levocetirizine 5mg NA 
5 mg od (≥ 6 
yr) 
Od: once daily, NA: Not available, mo: month, yr: year 
Adapted from Motala 2009.2 
 
Conclusion 
H1-antihistamines have a major role in allergic 
diseases; they are the main stay medications in 
allergic rhinoconjunctivitis and urticaria. 
Second-generation H1 antihistamines are 
preferred and more widely used owing to their 
better safety profile and efficacy than first- 
generation H1 antihistamines.  First- generation 
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H1 antihistamines are reserved for clinical 
situations where sedation or parenteral route is 
needed.  More studies are needed to evaluate 
H1 antihistamines efficacy, therapeutic 
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